Literature DB >> 16209895

Accuracy and conformity of stereotactically guided interstitial brain tumour therapy using I-125 seeds.

Harald Treuer1, Doris Klein, Mohammad Maarouf, Ralph Lehrke, Jürgen Voges, Volker Sturm.   

Abstract

OBJECTIVE: To assess the accuracy of the stereotactic implantation procedure of catheters containing I-125 seeds in brain tumours and investigate the effect of catheter deviations on the dose distribution in patients.
METHODS: A randomised sample (n = 37) of all patients treated with I-125 seeds in our department between 6/1994 and 2/2002 was examined. Intraoperative X-ray images were used to measure deviations of implanted I-125 seed catheters from their planned positions and the influence on dose conformity, tumour surface dose and dose burden of surrounding healthy brain tissue was determined.
RESULTS: The mean spatial target point deviation was 2.0 mm (maximum 4.1 mm, SD 0.9 mm) and in 54.1% of the cases, reduction of the planned dose was greater than 5%. Target point deviations less than 1.5 mm have only minor influence on surface dose and conformity. Results indicated that in 10.8% of the cases the realized dose distribution showed a 'slight deviation', according to the guideline criteria for external radiosurgery of the Radiation Therapy Oncology Group. In 89.2% of the patients the applied dose conformed to the target volume.
CONCLUSIONS: Stereotactically guided interstitial irradiation with I-125 seeds can be used to treat brain tumours and metastases with high conformity comparable to radiosurgery. The observed deviations of the stereotactically implanted I-125 seed catheters from their planned target points were smaller when compared to frameless procedures. In order to maintain the required spatial accuracy of 1.5 mm in interstitial therapy using I-125 seeds, it appears necessary to optimise stereotactic instruments further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16209895     DOI: 10.1016/j.radonc.2005.08.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery.

Authors:  Mohammad Maarouf; Faycal El Majdoub; Christian Bührle; Jürgen Voges; Ralph Lehrke; Martin Kocher; Stefan Hunsche; Harald Treuer; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.

Authors:  Philipp Kickingereder; Christina Hamisch; Bogdana Suchorska; Norbert Galldiks; Veerle Visser-Vandewalle; Roland Goldbrunner; Martin Kocher; Harald Treuer; Juergen Voges; Maximilian I Ruge
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

3.  Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases.

Authors:  Maximilian I Ruge; Martin Kocher; Mohammad Maarouf; Christina Hamisch; Harald Treuer; Jürgen Voges; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

4.  Intracavitary brachytherapy using stereotactically applied phosphorus-32 colloid for treatment of cystic craniopharyngiomas in 53 patients.

Authors:  Philipp Kickingereder; Mohammad Maarouf; Faycal El Majdoub; Manuel Fuetsch; Ralph Lehrke; Jochen Wirths; Klaus Luyken; Klaus Schomaecker; Harald Treuer; Juergen Voges; Volker Sturm
Journal:  J Neurooncol       Date:  2012-06-21       Impact factor: 4.130

5.  Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Stefan Grau; Mauritius Hoevels; Harald Treuer; Volker Sturm
Journal:  J Neurooncol       Date:  2011-04-11       Impact factor: 4.130

6.  Radiation protection of persons living close to patients with radioactive implants.

Authors:  Theodor W Kaulich; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2010-01-28       Impact factor: 3.621

7.  Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors.

Authors:  Faycal El Majdoub; Clemens Neudorfer; Tobias Blau; Martin Hellmich; Christian Bührle; Martina Deckert; Volker Sturm; Mohammad Maarouf
Journal:  Strahlenther Onkol       Date:  2015-08-26       Impact factor: 3.621

8.  Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children.

Authors:  Mohammad Maarouf; Faycal El Majdoub; Manuel Fuetsch; Mauritius Hoevels; Ralph Lehrke; Frank Berthold; Jürgen Voges; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2015-11-05       Impact factor: 3.621

9.  Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Thorsten Simon; Harald Treuer; Volker Sturm
Journal:  J Neurooncol       Date:  2012-05-12       Impact factor: 4.130

10.  Intracranial ependymoma: long-term results in a series of 21 patients treated with stereotactic (125)iodine brachytherapy.

Authors:  Faycal El Majdoub; Moataz Elawady; Tobias Blau; Christian Bührle; Mauritius Hoevels; Matthias Runge; Rolf-Peter Müller; Martina Deckert; Volker Sturm; Mohammad Maarouf
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.